Zymeworks Inc
Change company Symbol lookup
Select an option...
ZYME Zymeworks Inc
GRTS Gritstone bio Inc
QTWO Q2 Holdings Inc
DNAB Social Capital Suvretta Holdings Corp II
UPST Upstart Holdings Inc
GILT Gilat Satellite Networks Ltd
LAIXY LAIX Inc
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
OXBR Oxbridge Re Holdings Ltd
NVO Novo Nordisk A/S
Go

Health Care : Biotechnology | Small Cap Value
Based in Canada
Company profile

Zymeworks Inc. is a clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The Company operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. Its ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

Closing Price
$6.15
Day's Change
0.34 (5.85%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.26
Day's Low
5.80
Volume
(Heavy Day)
Volume:
696,590

10-day average volume:
517,410
696,590
Latest Earnings Met Consensus (Q2 ending 06/2022)Next Earnings Announcement
Q2
Announced August 4, 2022
-$0.97Q2 Estimate range
of 9 analysts
-$1.14 to -$0.78Q3 Earnings
will announce
(Unconfirmed) November 1, 2022

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

ZYME's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.